Viewing Study NCT04612751

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:45 PM
Ignite Modification Date: 2026-05-19 @ 12:13 AM
Study NCT ID: NCT04612751
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-18
First Post: 2020-10-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced or Metastatic NSCLC View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced or Metastatic NSCLC View
None Datopotamab deruxtecan (Dato-DXd) View
None DS-1062a View
None Durvalumab View
None AZD2936 View
None MEDI5752 View
None AZD7789 View